Novo Nordisk’s Rally Meets a Revenue Reckoning: Buyback Momentum Clashes with 2026 Guidance
Published on 07/17/2026 at 13:24 | Redaktion boerse-global.de
Novo Nordisk has staged a striking recovery over the past month, with the stock climbing 17% even as the company’s own 2026 revenue forecast points to a contraction of as much as 12%. That disconnect—between a surging share price and a shrinking top-line outlook—has become the central puzzle for investors weighing whether this is the start of a sustained turnaround or a technical rally that has run ahead of the fundamentals.
The Danish drugmaker is currently executing a share buyback program worth up to 15 billion Danish kroner, launched on February 4, 2026 and set to run for twelve months. According to the company’s most recent disclosure, it has already repurchased nearly 24 million B?shares at an average price of 272.45 kroner apiece, representing a total outlay of roughly €875 million. The buyback sends a clear signal of management’s confidence in its own cash generation and long?term value, but it also unfolds against a backdrop of expected revenue compression.
Technically, the stock has made substantial headway. At €44.46, it sits 47% above its March low of €30.25, yet it remains 27% below the record high of €60.95 set in July 2025. Over a trailing twelve months, the shares are still nursing a loss of about 21%. The 14?day relative strength index stands at 66.6, edging toward overbought territory, while the price trades 11% above its 50?day moving average of €40.04 and modestly above the 200?day average of €40.48. The stock’s ability to hold above these key technical levels has been a source of encouragement for bulls, but the longer?term trendline remains negative.
The Bull Case: Pill Progress and a Billion?Dollar Vote of Confidence
Optimists point to the rapid uptake of the oral version of Wegovy as the primary catalyst. The pill has now surpassed 3 million prescriptions in the United States, capturing 65% of all new GLP?1 scripts in the market, and CEO Mike Doustdar has described the situation as a “turnaround” in media interviews. Subject to regulatory approval, Novo Nordisk plans to launch the oral Wegovy in international markets during the second half of 2026, which would significantly expand its commercial reach.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the pipeline front, CagriSema—the company’s next?generation weight?loss candidate—has a U.S. Food and Drug Administration decision expected in the fourth quarter of 2026, with a potential market launch in early 2027. A favorable ruling would add a second powerful growth driver beyond the Wegovy pill. The ongoing buyback, financed alongside the dividend, further underscores the board’s belief that the current valuation underestimates the company’s future earnings power.
The Bear Case: Shrinking Revenue, Stiff Competition, and a Disappointing Trial
The most immediate headwind is the company’s own 2026 guidance, which calls for organic revenue growth of between negative 4% and negative 12% on a comparable basis. The contraction is driven primarily by pricing concessions in the U.S. market and the loss of exclusivity for semaglutide in several international markets. Even after the recent guidance revision—which narrowed a previously wider range—the business is still expected to shrink in absolute terms.
Competitive pressure is mounting. Eli Lilly’s oral tirzepatide product is already on the market, and while its early prescription numbers have lagged behind Wegovy’s at a comparable stage, the threat is far from neutralized. Novo Nordisk’s CEO has cautioned that the ramp?up of Lilly’s pill will take “quarters, not days.” More troubling, CagriSema itself stumbled in the head?to?head REDEFINE 4 trial: after 84 weeks, patients on CagriSema achieved 20.2% weight loss versus 23.6% on Lilly’s Zepbound, failing to demonstrate non?inferiority. That result raises questions about how the drug will differentiate commercially, even before the FDA has weighed in.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Adding to the uncertainty, the company is investigating a cyberattack in which a hacking group has claimed to have stolen internal data. On the technical side, the 17% surge in just 30 days—combined with an RSI approaching overbought—leaves the stock vulnerable to a pullback if any of the upcoming catalysts disappoint.
What to Watch Next
For now, the rally remains intact as long as the Wegovy pill continues to gain prescription share and the buyback proceeds on schedule. The next true test will come with the quarterly earnings release, which must show whether the operational momentum can offset the structural pricing headwinds. After that, the FDA’s decision on CagriSema in the fourth quarter of 2026 will be the critical catalyst that either validates the recovery narrative or exposes it as a rally built on hope rather than substance.
Ad
Novo Nordisk Stock: New Analysis - 17 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
